Antibody Information
General Information of This Antibody (ID: ANTI0HLPRM)
| Antibody Name | A bispecific anti-EGFR/c-Met bsAb |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | EGFR; c-Met |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
PRO-1286 [Phase 1/2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: age ≥18; ECOG 0-1; measurable advanced solid tumors (RECIST 1.1); refractory to standard therapies; adequate organ function; willingness to provide tumor samples.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06685068 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary endpoints include AE incidence (NCI-CTCAE v5.0) over 3 years 9 months and DLTs during first cycle (21 days) for GEN1286 safety evaluation.
|
||||
| Other Endpoint |
Secondary endpoints comprise efficacy measures (ORR, DCR, PFS, DOR per RECIST 1.1) and PK parameters (AUC, Cmax, Tmax, t1/2, CL, Vz, Ctrough of antibody-conjugated exatecan components) over 2 years 9 months, plus ADA assessment.
|
||||
DM005 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Key inclusion criteria: signed consent; age ≥18; advanced/metastatic solid tumors (NSCLC, gastroesophageal/colorectal/HCC/pancreatic/HNSCC) refractory to standard therapy; ECOG 0-2; life expectancy ≥3 months; measurable disease (RECIST 1.1).
|
||||
| Administration Dosage |
An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W, 0.5, 1, 2, 4, 6, 8 mg/kg.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06515990 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1, Multicenter, Open-label, First-in-human, Dose Escalation and Expansion Study of DM005 in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary endpoints include DLT incidence (grade 3 neurological/grade 4 toxicities) and MTD determination (0/3 or 1/6 DLT rate) for DM005 over 12 months.
|
||||
| Other Endpoint |
Secondary endpoints comprise PK parameters (AUC, Cmax, Tmax, Ctrough) and ORR assessment (RECIST v1.1) within 12 months.
|
||||
References